COVAX

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

Nanotechnology Revolutionizes Industrial Packaging as Market Expands at 5.02% CAGR

Retrieved on: 
Saturday, November 11, 2023
Sale, Agriculture, Sonoco, International Paper, Plastic, Sealed Air, Safety, Final good, Dust, Ultimate tensile strength, Urbanization, ROW, Food, Corporation, PCA, HBV, Steel, Internet access, Lubricant, Grain, Horticulture, COVID-19, Natural gas, Compound annual growth rate, Grief, COVAX, Nanotechnology, Amcor, Growth, Population growth, Common, FMCG, IBC, WestRock, Transport, Nanoparticle, Video game

The global industrial packaging market is poised for substantial growth, projected to achieve a market value of US$68.91 billion by 2023, with a notable Compound Annual Growth Rate (CAGR) of 5.02% during the forecast period.

Key Points: 
  • The global industrial packaging market is poised for substantial growth, projected to achieve a market value of US$68.91 billion by 2023, with a notable Compound Annual Growth Rate (CAGR) of 5.02% during the forecast period.
  • Industrial packaging encompasses specialized, durable packaging solutions designed for the wrapping, containment, and sealing of FMCG during storage and distribution.
  • The global industrial packaging market is segmented by material type into seven categories: corrugated boxes, intermediate bulk containers (IBC), sacks, drums, pails, crates, and others.
  • Protective industrial packaging is also essential for the secure transportation of goods, including potential product returns, further boosting the industrial packaging market.

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Technology, Infectious Diseases, Health, Artificial Intelligence, WHO, Bioinformatics, LG Chem, Drug design, Intelligence, Composition, Incidence, Pregnancy, Vaccine, Government, ROW, Prevalence, Indian Immunologicals Limited, GSK plc, Merck, Data science, Mother, Vaccination, Liver cancer, Genomics, Transport, COVAX, COVID-19, Antibody, KM, Microbiology, Machine learning, Biochemistry, Blood, Hepatitis A and B vaccine, Serum, Hepatitis B virus, Public, Sanofi, Hepatitis, Hepatitis B, Immunization, Pediatrics, World Health Organization's response to the COVID-19 pandemic, Compound annual growth rate, HBV, Parent, Cirrhosis, Merck & Co.

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.

Understanding the Principles of Socio-economic Equality for a Fair Post-pandemic Society

Retrieved on: 
Wednesday, October 11, 2023
Element, COVID-19, Vaccination, Vaccine, COVAX, Freedom, Tourism, Chiba University, Coronavirus

CHIBA, Japan, Oct. 11, 2023 /PRNewswire/ -- The Coronavirus (COVID-19) pandemic has led to significant losses on a global scale since 2019. As we continue to recover from its after-effects, there is an unmet need to address social inequality across different populations to minimize long-term damage. However, the definition of fairness differs contextually with respect to the COVID-19 crisis.

Key Points: 
  • As we continue to recover from its after-effects, there is an unmet need to address social inequality across different populations to minimize long-term damage.
  • However, the definition of fairness differs contextually with respect to the COVID-19 crisis.
  • In summary, the book highlights familial, societal, national, and global issues raised by the COVID-19 pandemic and provides novel insights into the structuring of a fair post-pandemic society.
  • Explaining the long-term implications of their work, Dr. Ishido concludes by stating, "As an interdisciplinary work, these findings could advance our understanding of how a post-pandemic society could emerge, based on the four inseparable components of fairness."

WHO Muzzles Critics to Dominate Pandemic Treaty Dialog, says AHF

Retrieved on: 
Wednesday, July 19, 2023
Public Policy, Government, Pharmaceutical, AIDS, Health, Healthcare Reform, Infectious Diseases, Advocacy Group Opinion, Other Health, AHF, COVID-19, INB, COVAX, WHO, Pandemic, AIDS Healthcare Foundation, World Health Organization, Intergovernmental, Pharmaceutical industry

“We object to the notion that parties with ‘vested interests,’ who want to see a meaningful and enforceable draft of a new pandemic accord – one that is transparent, accountable, and cooperative – are attempting to disrupt negotiations at the current INB meeting,” said AHF President Michael Weinstein.

Key Points: 
  • “We object to the notion that parties with ‘vested interests,’ who want to see a meaningful and enforceable draft of a new pandemic accord – one that is transparent, accountable, and cooperative – are attempting to disrupt negotiations at the current INB meeting,” said AHF President Michael Weinstein.
  • “They’re likely pointing out that it is, in fact, a WHO power grab, which has a subpar record at best in handling global public health emergencies.
  • Increasing the existing WHO sphere of influence, protecting big pharma, and allowing only wealthy countries to lead the dance is not the answer.
  • We must do better collectively if the world is to be positioned to prevent, prepare for, and respond to future inevitable pandemics.

Highlights - Exchange of views with Comissioner Urpilainen & Executive Vice President Dombrovskis - Special Committee on the COVID-19 pandemic: lessons learned and recommendations for the future

Retrieved on: 
Sunday, February 26, 2023
Civil service commission, TRIPS, Commissioner, Pandemic, World Trade Organization, Executive Vice President of the European Commission for An Economy that Works for People, Emergency, COVAX, World, European Commission, Vaccine, Developed country, Tourism

Exchange of views with Comissioner Urpilainen & Executive Vice President Dombrovskis

Key Points: 
  • Exchange of views with Comissioner Urpilainen & Executive Vice President Dombrovskis
    On Monday 27 February, Commissioner for International Partnerships Jutta Urpilainen and Executive Vice President of the European Commission and Commissioner for Trade Valdis Dombrovskis will be present for an exchange of views in the COVI Special Committee.
  • The exchange of views will also look at short- and medium-term European solutions to prevent and manage shortages of essential medicines, the global pandemic treaty and the World Trade Organization negotiated agreement on TRIPS.
  • It will examine the European Commission's plans to drive international cooperation towards a global commitment which would prevent future pandemics, while preparing a system of international trade fit for emergencies.
  • The meeting will also look at how Europe can become strategically autonomous on health-related matters.

EQS-News: Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance

Retrieved on: 
Wednesday, February 22, 2023
MBA, Vaccine, Infection, HPV, COVAX, Global health, News, CEPI, Harvard University, Internal medicine, Primary health care, Death, Minister, Duke University, Health equity, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Knowledge, Berkley, Public health, Global Financing Facility, Secretariat, Bank, Public, World Bank, COVID-19, Cholera, UNAIDS, Mark R. Dybul, Julio Frenk, Malaria, Pharmaceutical industry, Security (finance), Management, Health

Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance

Key Points: 
  • Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance
    The issuer is solely responsible for the content of this announcement.
  • Dr Pate will be officially starting as CEO on 3 August 2023.
  • Dr Muhammad Ali Pate, who was selected following a yearlong recruitment process personally overseen by the Chair of the Gavi Board, Professor José Manuel Barroso, will bring a wealth of experience to the role.
  • Commenting on the appointment, Professor Barroso said: “Dr Muhammad Ali Pate stood out in a field of world-class candidates.

EQS-News: Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance

Retrieved on: 
Monday, February 20, 2023
MBA, Vaccine, Infection, HPV, COVAX, Global health, News, CEPI, Harvard University, Internal medicine, Primary health care, Death, Minister, Duke University, Health equity, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Knowledge, Berkley, Public health, Global Financing Facility, Secretariat, Bank, Public, World Bank, COVID-19, Cholera, UNAIDS, Mark R. Dybul, Julio Frenk, Malaria, Pharmaceutical industry, Security (finance), Management, Health

Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance

Key Points: 
  • Gavi, The Vaccine Alliance: Dr Muhammad Ali Pate to become next Chief Executive Officer (CEO) of Gavi, the Vaccine Alliance
    The issuer is solely responsible for the content of this announcement.
  • Dr Pate will be officially starting as CEO on 3 August 2023.
  • Dr Muhammad Ali Pate, who was selected following a yearlong recruitment process personally overseen by the Chair of the Gavi Board, Professor José Manuel Barroso, will bring a wealth of experience to the role.
  • Commenting on the appointment, Professor Barroso said: “Dr Muhammad Ali Pate stood out in a field of world-class candidates.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on: 
Thursday, December 15, 2022
Pfizer, Vaccination, United Arab Emirates, Transport, Omicron, Sinopec, Sinovac Biotech, Research, CanSino Biologics, Immunization, Wellcome Trust, World Health Organization, COVID-19, Vaccine, News, WHO, Safety, COVID-19 vaccine, COVAX, Risk, Pharmaceutical industry, Animal, China National Pharmaceutical Group

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points: 
  • In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
  • Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
  • As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
  • It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.

CGTN: How China strengthens vaccine cooperation to battle COVID-19

Retrieved on: 
Thursday, December 15, 2022
Pfizer, Vaccination, United Arab Emirates, Transport, Omicron, Sinopec, Sinovac Biotech, Research, CanSino Biologics, Immunization, Wellcome Trust, World Health Organization, COVID-19, Vaccine, News, WHO, Safety, COVID-19 vaccine, COVAX, Risk, Pharmaceutical industry, Animal, China National Pharmaceutical Group

In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.

Key Points: 
  • In March 2020, the adenovirus vector vaccine developed by a team led by Chinese military medical scientist Chen Wei became the first vaccine in China approved to enter clinical trials.
  • Other COVID-19 vaccine research had been carried out concurrently, including the inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm) and the inactive one from Beijing-based pharmaceutical company Sinovac.
  • As the virus keeps mutating, China has continued to advance its vaccine research over the past three years.
  • It was the first Chinese vaccine officially recognized by the WHO and the sixth vaccine approved for emergency use globally.